What is Entopsis?
Entopsis, headquartered in Miami, Florida, is at the forefront of molecular identification technology. The company's proprietary NuTec platform employs a novel chemical hashing approach to analyze biomolecules, enabling the rapid detection of multiple analytes from diverse sample types. This technology holds the potential to revolutionize clinical diagnostics by consolidating multiple disease diagnoses into a single device, moving away from the current reliance on numerous individual tests. Entopsis is dedicated to creating accessible and cost-effective solutions for routine health monitoring and has achieved ISO certification for its device manufacturing and sales.
How much funding has Entopsis raised?
Entopsis has raised a total of $800K across 1 funding round:
Angel/Seed
$800K
Angel/Seed (2015): $800K with participation from Krillion Ventures
Key Investors in Entopsis
Krillion Ventures
Krillion Ventures is a Miami-based venture capital fund that invests in early stage technology companies focused on healthcare, financial services, and real estate. The firm seeks to partner with innovative and driven entrepreneurs who challenge the status quo and inspire others.
What's next for Entopsis?
With its recent major strategic investment, Entopsis is poised to accelerate the development and commercialization of the NuTec platform. The substantial capital infusion is expected to fuel further research and development, scale manufacturing capabilities, and expand market reach into critical sectors like food safety and medicine. This funding round signals a pivotal growth phase for Entopsis, positioning it to disrupt traditional diagnostic methods and establish a new standard for molecular identification and multi-disease diagnostics.
See full Entopsis company page
